Expert consensus on the management of chronic lymphocytic leukaemia in Asia

In recent years, considerable progress has been made in the standard treatment for chronic lymphocytic leukaemia (CLL) due to the availability of new potent drugs. However, the majority of data on CLL were derived from Western populations, with limited studies and guidelines on the management of CLL...

Descripción completa

Detalles Bibliográficos
Autores principales: Tse, Eric, Kwong, Yok Lam, Goh, Yeow Tee, Bee, Ping Chong, Ng, Soo Chin, Tan, Daryl, Caguioa, Priscilla, Nghia, Huynh, Dumagay, Teresita, Norasetthada, Lalita, Chuncharunee, Suporn, Radhakrishnan, Vivek, Bagal, Bhausaheb, Atmakusuma, Tubagus Djumhana, Mulansari, Nadia Ayu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543526/
https://www.ncbi.nlm.nih.gov/pubmed/36795237
http://dx.doi.org/10.1007/s10238-023-01007-2
Descripción
Sumario:In recent years, considerable progress has been made in the standard treatment for chronic lymphocytic leukaemia (CLL) due to the availability of new potent drugs. However, the majority of data on CLL were derived from Western populations, with limited studies and guidelines on the management of CLL from an Asian population perspective. This consensus guideline aims to understand treatment challenges and suggest appropriate management approaches for CLL in the Asian population and other countries with a similar socio-economic profile. The following recommendations are based on a consensus by experts and an extensive literature review and contribute towards uniform patient care in Asia.

Ejemplares similares